Trastuzumab deruxtecan demonstrated durable responses and a safety profile that was consistent with findings from the primary analysis of the phase 2 DESTINY-CRC01 trial in pretreated patients with HER2-expressing metastatic colorectal cancer, according to updated results of the study.
The addition of nivolumab to encorafenib and cetuximab elicited a high response rate and an acceptable safety profile in patients with refractory microsatellite stable, BRAF V600E–mutant metastatic colorectal cancer, according to findings from a phase 1/2 trial.
Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.
The use of pembrolizumab plus binimetinib and bevacizumab in patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer induced a median progression-free survival of 5.8 months, according to preliminary findings from a phase 2 trial.
Onvansertib in combination with irinotecan, fluorouracil, and folinic acid, plus bevacizumab, demonstrated encouraging efficacy and was well-tolerated in patients with KRAS-mutated metastatic colorectal cancer.
Transarterial chemoembolization plus lenvatinib led to a significant improvement in overall survival vs lenvatinib alone as frontline therapy in patients with advanced hepatocellular carcinoma, according to findings from the phase 3 LAUNCH trial.
Do-Youn Oh, MD, PhD, discusses the results of the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.
David S. Hong, MD, discusses the efficiency of the ongoing phase 1/2 CodeBreaK 101 trial in KRAS G12C-mutated advanced colorectal cancer and other solid tumors.
Tanios S. Bekaii-Saab, MD, FACP, discusses the updated results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C-mutated gastrointestinal cancers, including pancreatic ductal adenocarcinoma.
Updated findings from the KEYNOTE-590 study confirmed the clinical benefit of the combination of pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer.
Thomas A. Abrams, MD, discusses the rationale for the ongoing phase 1/2 COSMIC-021 trial in microsatellite stable and mismatch repair proficient colorectal cancer.
Kanwal P.S. Raghav, MBBS, MD, discusses the rationale for the ongoing phase 2 DESTINY-CRC02 trial in HER2-overexpressing metastatic colorectal cancer.
Lenvatinib was effective in treating patients with recurrent hepatocellular carcinoma after liver transplantation and demonstrated manageable toxicities.
Nivolumab plus chemotherapy demonstrated a durable survival benefit for patients with gastric or gastroesophageal junction cancer, according to updated findings from the CheckMate 649 trial.
Sintilimab plus standard-of-care chemotherapy failed to demonstrate a significant improvement in overall survival and progression-free survival vs standard-of-care chemotherapy alone but did result in an improved objective response rate in patients with metastatic or recurrent pancreatic adenocarcinoma, according to findings from the phase 3 CISPD3 trial.
The oral fluoropyrimidine derivative S-1 led to improved survival when used as adjuvant therapy compared with surgery alone in patients with biliary tract cancers.
Adagrasib monotherapy demonstrated encouraging clinical activity in patients with previously treated pancreatic ductal adenocarcinoma and other non–colorectal gastrointestinal tumors that harbor KRAS G12C mutations.
Although pembrolizumab monotherapy showed noninferiority to chemotherapy for overall survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher, and a clinically meaningful benefit over chemotherapy in those with a CPS of 10 or higher, pembrolizumab plus chemotherapy failed to show superiority over chemotherapy alone in either subset.
The presence of Arthrobacter and fatty acid metabolism pathways in gut microbiomes may be linked to an increased risk of skin-related adverse events in patients with advanced gastric cancer who are receiving single-agent nivolumab.
Neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab elicited a pathologic complete response rate of 59% in patients with resectable microsatellite instable or mismatch repair deficient oeso-gastric junction adenocarcinoma.
Heinz-Josef Lenz, MD, FACP, discusses the rationale for the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.
Edmund Scott Kopetz, MD, PhD, FACP, discusses the rationale for the ongoing phase 3 BREAKWATER trial in BRAF V600E-mutant metastatic colorectal cancer.
The combination of durvalumab and tremelimumab demonstrated a significant improvement in overall survival vs sorafenib as frontline therapy in patients with unresectable hepatocellular carcinoma, according to findings from the phase 3 HIMALAYA trial.
Treatment with the PD-L1 inhibitor durvalumab in combination with gemcitabine and cisplatin resulted in significantly improved overall survival vs placebo plus chemotherapy in patients with advanced biliary tract cancer.
The investigational bispecific antibody APVO436 demonstrated tolerability with encouraging anti-neoplastic efficacy in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome, according to updated findings from an ongoing phase 1 trial.
Elevated amphiregulin was associated with increased mortality risk in acute graft–versus-host-disease, according to a sample of 2 prospective clinical trials showed.
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone continued to elicit improved outcomes vs RVd alone in patients with newly diagnosed, transplant-eligible multiple myeloma, according to findings from the extended 2-year follow-up analysis of the phase 2 GRIFFIN trial.
Treatment with the CD123- and CD3-engaging bispecific antibody APVO436 caused cytokine release syndrome in approximately 1 of 5 patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome but was generally well managed with steroids.
Patients with relapsed or refractory large B-cell lymphoma experienced better quality of life when they received second-line treatment with lisocabtagene maraleucel vs standard of care.
A single infusion of ciltacabtagene autoleucel produced an overall response rate of 95% in patients with multiple myeloma who had received a median of 2 prior lines of treatment and who were refractory to lenalidomide.
